Imatinib Mesylate in Advanced Dermatofibrosarcoma Protuberans: Pooled Analysis of Two Phase II Clinical Trials
Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Scott M. Schuetze(Cleveland Clinic), Maria Dêbiec‐Rychter(Catholic University of America), Dolores López‐Terrada(Cleveland Clinic), Hans Gelderblom(Leiden University Medical Center), Peter Hohenberger(Centre Oscar Lambret), Alexander J. Lazar(Cleveland Clinic), Raf Sciot(Cleveland Clinic), M. van Glabbeke(European Organisation for Research and Treatment of Cancer), Allan T. van Oosterom(Cleveland Clinic), Brian P. Rubin(Cleveland Clinic), W. Ruka(Cleveland Clinic), Cathryn Rankin(Cleveland Clinic)
Cited by 401
Related Papers
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501)
|Head & Neck|2005|1.8k
Cremophor EL
|European Journal of Cancer|2001|1.6k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k